The 55 references in paper K. Komissarov S., M. Yurkevich Ju., M. Zafranskaya M., V. Pilotovich S., К. Комиссаров С., М. Юркевич Ю., М. Зафранская М., В. Пилотович С. (2014) “Современные представления о патогенезе иммуноглобулин А-нефропатии // Modern insights on IgA nephropathy pathogenesis” / spz:neicon:nefr:y:2014:i:2:p:47-54

1
Berger J, Hinglais N. Intercapillary deposits of IgA-IgG. J Urol Nephrol 1968; 74: 694-695
(check this in PDF content)
2
Monteiro RC. New insights in the pathogenesis of IgA nephropathy. Nephrologia 2005; 25 (suppl. 2): 82 – 86
(check this in PDF content)
3
Feehally J, Allen A. Structural features of IgA molecules which contribute to IgA nephropathy. J Nephrol 1999; 12: 59–65
(check this in PDF content)
4
D’Amico G. Idiopathic IgA mesangial nephropathy. Clinical and histological study of 374 patients. Medicine (Baltimore) 1985; 64: 49–60
(check this in PDF content)
5
Allen AC, Bailey ЕМ, Barratt J et al. Analysis of IgAl OGlycans in IgA Nephropathy by Fluorophore-Assisted Carbohydrate Electrophoresis. J Am Soc Nephrol 1999; 10: 1763-1771
(check this in PDF content)
6
Hiki Y, Kokubo T, Lwase H et al. Underglycosylation of IgAl Hinge Plays a Certain Role for Its Glomerular Deposition in IgA Nephropathy. J Am Soc Nephrol 1999; 10: 760-769
(check this in PDF content)
7
Giannakakis K. Abberantly glycosylated IgA1 in glomerular immune deposits of IgA nephropathy. J Am Soc Nephrol 2007; 18: 3139-3146
(check this in PDF content)
8
Tomana M, Novak J, Julian BA, et al. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest 1999; 104: 73–81
(check this in PDF content)
9
Yamada K, Kobayashi N, Ikeda T, et al. Down-regulation of core 1 {beta}1,3-galactosyltransferase and Cosmc by Th2 cytokine alters O-glycosylation of IgA1. Nephrol Dial Transplant 2010; 25: 3890–3897
(check this in PDF content)
10
Suzuki H, Moldoveanu Z, Hall S, et al. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest 2008; 118: 629–639
(check this in PDF content)
11
Zhu L, Tang W, Li G et al. Interaction between variants of two glycosyltransferase genes in IgA nephropathy. Kidney Int 2009; 69: 190–198
(check this in PDF content)
12
Gharavi AG, Moldoveanu Z, Wyatt RJ et al. Abberant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol 2008; 19: 1008–1014
(check this in PDF content)
13
Suzuki H. IgA1 secreting cell lines from patients with IgA nephropathy produce aberrantly glycosilated IgA1. J Clin Invest 2008; 118: 629–639
(check this in PDF content)
14
Glassock RJ. Analyzing antibody activity in IgA nephropathy. J Clin Invest 2009; 119: 1450-1452
(check this in PDF content)
15
Feehally J, Farrall M, Boland A, et al. HLA has strongest association with IgA nephropathy in genome-wide analysis. J Am Soc Nephrol 2010; 21: 1791–1797
(check this in PDF content)
16
Monteiro RC, Van De Winkel JG. IgA Fc receptors. Annu Rev Immunol 2003; 21: 177 – 204
(check this in PDF content)
17
Launay P, Grossette B, Arcos-Fajardo M et al. Fc_receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger’s disease). Evidence for pathogenic soluble receptor – IgA complexes in patients and CD89 transgenic mice. J Exp Med 2000; 191:1999 – 2009
(check this in PDF content)
18
Oortwijn BD, Rastaldi MP, Roos A. Demonstration of secretory IgA in kidneys of patients with IgA nephropathy. Nephrol Dial Transplant 2007; 22: 3191–3195
(check this in PDF content)
19
Roos A, Rastaldi MP, Calvaresi N et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol
(check this in PDF content)
20
6; 1724–1734 20. Harper SJ, Allen AC, Pringle JH et al. Increased dimeric IgA producing B cells in the bone marrow in IgA nephropathy determined by in situ hybridisation for J chain mRNA. J Clin Pathol 1996; 49: 38–42
(check this in PDF content)
21
Buren M, Yamashita M, Suzuki Y et al. Altered expression of lymphocyte homing chemokines in the pathogenesis of IgA nephropathy. Contrib Nephrol 2007; 157: 50–55
(check this in PDF content)
22
Batra A, Smith AC, Feehally J et al. T-cell homing receptor expression in IgA nephropathy. Nephrol Dial Transplant 2007; 22: 2540–2548
(check this in PDF content)
23
Akira S. Mammalian Toll-like receptors. Curr Opin Immunol 2003; 15: 5–11
(check this in PDF content)
24
Blaas SH, Stieber-Gunckel M, Falk W et al. CpG-oligodeoxynucleotides stimulate immunoglobulin A secretion in intestinal mucosal B cells. Clin Exp Immunol 2009; 155: 534–540
(check this in PDF content)
25
Qin W, Zhong X, Fan JM et al. External suppression causes the low expression of the Cosmc gene in IgA nephropathy. Nephrol Dial Transplant 2008; 23: 1608–1614
(check this in PDF content)
26
Kar Neng Lai, Loretta YY Chan, Sydney C.W. Tang et al. Characteristics of Polymeric R-IgA Binding to Leukocytes in IgA Nephropathy. J Am Soc Nephrol 2002; 13: 2309-2319
(check this in PDF content)
27
Floege J, Feehally J. IgA nephropathy resent development. J Am Soc Nephrol 2000; 11: 2395-2403
(check this in PDF content)
28
Suzuki H, Fan R, Zhang Z et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 2009; 119 (6): 16681677
(check this in PDF content)
29
Moura IC, Benhamou M, Launay P, Vrotvsnik F, Blank U, Monteiro RC. The glomerular response to IgA deposition in IgA nephropathy. Semin Nephrol 2008; 28: 88–95
(check this in PDF content)
30
Barratt J. IgA nephropathy. J Am Soc Nephrol 2005; 19: 2088-2097
(check this in PDF content)
31
Endo M, Ohi H, Ohsawa I. et al. Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy. Nephrol Dial Transplant 1998; 13: 1984–1990
(check this in PDF content)
32
Wyatt RJ, Kanayama Y, Julian B et al. Complement activation in IgA. Nephropathy. Kidney Int 1987; 31: 1019–1023
(check this in PDF content)
33
Barratt J, Feehally J, Smith A. Pathogenesis of IgA nephropathy. Seminar in Nephrology 2004; 24; 3: 197-217
(check this in PDF content)
34
Батурина ТВ, Сергеева ТВ. Цитокины и адгезивные молекулы в патогенезе хронического гломерулонефрита. Нефрология и диализ 2002; 4; 3: 232-239
(check this in PDF content)
35
Yokoyama H, Takaeda M, Wada T et al. Glomerular ICAM-1 expression related to circulating TNF-alpha in human glomerulonephritis. Nephron 1997; 76; 4: 425-433
(check this in PDF content)
36
Alexopoulos E, Seron D, Hartley RB et al. The role of interstitial infiltrates in IgA nephropathy: a study with monoclonal antibodies. Nephrol Dialysis Transplant 1989; 4: 187–195
(check this in PDF content)
37
Gуmez-Guerrero C, Gonzlez E, Hernando P et al. Interaction of mesangial cells with IgA and IgG immune complexes: a possible mechanism of glomerular injury in IgA nephropathy. Contrib Nephrol. Basel, Karger 1993; 104: 127–137
(check this in PDF content)
38
Chen HC, Guh JY, Chang JM et al. Differential effects of circulating IgA isolated from patients with IgA nephropathy on superoxideand fibronectin production of mesangial cells. Nephron 2001; 88: 211–217
(check this in PDF content)
39
Vas T, Wagner Z, Jenei V et al. Oxidative stress and nonenzymatic glycation in IgA nephropathy. Clin Nephrol 2005; 64: 343–351
(check this in PDF content)
40
Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T et al. Early prediction of IgA nephropathy progression: proteinuria and AOPP are strong prognostic markers. Kidney Int 2004; 66: 1606–1612
(check this in PDF content)
41
Coppo R, Feehally J, Glassock RJ. IgA nephropathy at two score and one. Kidney Int 2010; 77: 181–186
(check this in PDF content)
42
Yang CW, Hsueh S, Wu MS et al. Glomerular transforming growth factor-β1mRNA as a marker of glomerulosclerosis-application in renal biopsies. Nephron 1997; 77: 290-297
(check this in PDF content)
43
Iwano M, Akai Y, Fujii Y et al. Intraglomerular expression of transforming growth factor-beta 1 (TGF-beta 1) mRNA in patients with glomerulonephritis: quantitative analysis by competitive polymerase chain reaction. Clin Exp Immunol 1994; 97: 309-314
(check this in PDF content)
44
Donadio J, Grande J. IgA nephropathy. N Engl J Med 2002; 347: 738-748
(check this in PDF content)
45
Wada T, Hamakawa S, Hori Y et al. Immunohistochemical localization of latent transforming growth factor-β binding protein in IgA nephropathy. Kidney Int 1997; 63 [Suppl 3]: 182-184
(check this in PDF content)
46
Lai K, Ho R, Leung J et al. Increases mRNA encoding for transforming growth factor-β in CD4+ cells from patients with IgA nephropathy. Kidney Int 1994; 46: 862-868
(check this in PDF content)
47
Sang-Youb H, Chun-Gyoo Ihm, Dae-Ryong Cha et al. Effect of IgA aggregates on transforming growth factor-β1 production in human mesangial cells and the intraglomerular expression of transforming growth factor-β1 in patients with IgA nephropathy. The Korean Journal of Internal Medicine 2005; 20: 40 – 47
(check this in PDF content)
48
Li B, Khanna A, Sharma V et al. TGF-beta1 DNA polymorphisms, protein levels, and blood pressure. Hypertension 1999; 33: 271-275
(check this in PDF content)
49
Haramaki R, Tamaki K, Fujisawa M et al. Steroid therapy and urinary transforming growth factor-beta1 in IgA nephropathy. Am J Kidney Dis 2001; 38: 1191-1198
(check this in PDF content)
50
Floege J, Eitner F, Alpers C. A new look at platelet-derived growth factor in renal disease. J Am Soc Nephrol 2008; 19: 12–23
(check this in PDF content)
51
Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79: 1283–1316, 1999
(check this in PDF content)
52
Boor P, Eitner F, Cohen CD et al. Patients with IgA nephropathy exhibit high systemic PDGF-DD levels. Nephrol Dial Transplant 2009; 24: 2755 – 2762
(check this in PDF content)
53
Ostendorf T, van Roeyen CR, Peterson JD et al. A fully human monoclonal antibody (CR002) identifies PDGF-D as a novel mediator of mesangioproliferative glomerulonephritis. J Am Soc Nephrol 2003; 14: 2237–2247
(check this in PDF content)
54
Daynes R, Dowell T, Araneo B. Platelet-derived growth factor is a potent biologic response modifier of T cells. J Exp Med 1991; 174: 1323–1333
(check this in PDF content)
55
A Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 2009; 76: 546–556 Авторы заявляют об отсутствии конфликта
(check this in PDF content)